This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
5 Q&As
Facts about Carbonic anhydrase 12.
Human | |
---|---|
Gene Name: | CA12 |
Uniprot: | O43570 |
Entrez: | 771 |
Belongs to: |
---|
alpha-carbonic anhydrase family |
CA12; Carbonate dehydratase XII; carbonic anhydrase 12; Carbonic Anhydrase XII; carbonic anhydrase XIICAXII; carbonic dehydratase; CA-XII; EC 4.2.1.1; FLJ20151; HsT18816; Tumor antigen HOM-RCC-3.1.3
Mass (kDA):
39.451 kDA
Human | |
---|---|
Location: | 15q22.2 |
Sequence: | 15; NC_000015.10 (63321378..63382110, complement) |
Highly expressed in colon, kidney, prostate, intestine and activated lymphocytes. Expressed at much higher levels in the renal cell cancers than in surrounding normal kidney tissue. Moderately expressed in pancreas, ovary and testis.
Membrane; Single-pass type I membrane protein. Cell membrane.
We'll be discussing Anti CA XII CA12Marker (High-affinity primary antibodies) and Clinical applications. We will also discuss Steven Boster’s background and the CA12Marker. This article is for scientific researchers who need help identifying an antigen in animal tissue or human tissue. It's not just for scientists in the United States. Scientists from around the world can benefit from this product.
We are currently developing a biomarker that can detect lung cancer by using the anti-CA XII CA12 antigen. This peptide targets CAXII and is highly expressed in lung tumors. The marker can then be used to develop targeted therapeutics or imaging probes. In the end, it may improve patient care. This study confirms the utility of the new biomarker.
Boster Biologicals has developed this antibody. It reacts to human, mouse, rat, or rat samples. It is used for research, diagnosis of cancer, and other purposes. The anti-CA XII CA12 antibody is so sensitive it can detect the biomarker down to a picogram level. Boster Biologicals' immunological reagents can be purchased through their website, tebu-bio.
Multiple clinically relevant biomarkers are associated with CA12 mRNA expression. CA12 expression predicts poor clinical outcomes for Asian patients with advanced gliomas. CA12 expression correlates also with IDh2WTDNA, a clinical molecular marker, which is a codeletion of 1p19q DNA chromosome arm and WHO grade 4 tumor stage. Additionally, tumors that have high levels of CA12 expression cluster in the mesenchymal transcript subclass. CAXII levels range from very low to high, with no correlation with stem-cell markers.
The anti-CA XII CA12 biopsy has shown promise in lung cancer therapy. Its bivalent targeting antibody may be used to help patients diagnose their condition. Physicians can also use the same biomarker for cytotoxic drugs. This drug is safe and could be used to treat lung cancer. This biomarker is not only expected to improve patient outcomes, but it may also be used to detect other diseases in a more specific way.
High-affinity primary antibody using the CA-12 marker is monoclonal or multiclonal monoclonal antibodies raised against a specific protein. Primary antibodies are capable of recognizing post-translational modifications, analysing components of living cells at molecular level, as well as detecting proteins involved in diseases. GenScript has a wide range of primary antibodies that are high-affinity and covers the most important areas in life science research.
The secondary antibody, a synthetic protein, has been conjugated to many different labels. The choice depends on how the primary antibody will be used and the type of detection needed. HRP is the most common type of label, but alkaline phosphatase is relatively cheaper and more stable. However, it is not as sensitive as HRP. The latter is generally more sensitive than HRP.
The optimal concentration for primary antibody should be between 1.7 to 15 Ug/mL. The same goes for the diluent. The monoclonal and the polyclonal antibodies should have KD values in the range of 5-25 ug/mL, respectively. In addition to the concentration of the primary antibody, the length of time needed for incubation is important, since it affects signal quality.
A diluted solution containing Nova-red or Vector blue should be used for the detection of the primary antibody. Once the first primary antibody has been detected, a diluted solution of Nova-red or Vector Blue should be used. The second one should then be applied. It is possible to use a second primary antigen, but this requires double-staining. Also, the second must be different in color from the first. After the dilution step, the buffer should then be replaced by another color-sensitive substance.
High-affinity antibodies can be produced using immobilized serum proteins, or a combination. Using this process, the antibodies can be purified by multiple primary antibodies using the same antigen. Cross-adsorption can be used to purify antibodies using multiple primary antibodies. This is highly recommended in applications where multiple primary antibody are required. This method can also be used if you have multiple primary antibodies.
The CA12 marker, a membrane-associated protein, is expressed in many human cancers. Its low prognostic power makes it an attractive target for cancer treatment. We have developed humanized CA12 antibodies in this study. We created antibody libraries by using Retrocyte display (r) and screened them for antigen binding properties using ELISA and flow cytometry. To assess the viability of spheroids, we also performed cell-titer fluor assays.
The CA12 marker was used for many years and has undergone many improvements in the past decade. Its widespread clinical use is limited by the low incidence of cancer in asymptomatic patients. Tumor markers still have some diagnostic value in certain situations. They are most often used in primary care to detect disease recurrence or follow treatment response. They can also indicate the need to have second-look surgery.
The CA12 marker is used in noninvasive tumor screening. The CTC counts have the potential to greatly improve cancer patient care. It can be used to detect cancer cells in your circulatory system before they become metastatic. Unlike invasive procedures, the CTC count can detect CTCs before tumors grow in the breast. These cells could represent tumors coming from two different sources.
Stephen "Steve" Boster (born May 31, 1939, Joliet IL). He was the son of James and Evelyn Meier Boster. He was a long-standing retail sales manager and was a proud Concordia Hall Member in Staunton. Many nieces, nephews, and great-grandchildren survived Steve.
Steve's love for family was his greatest asset. His passion for the lowest register of singing was only matched by his love to his sons. He also loved sports, especially auto racing. He was the first one to call when his vehicle broke down at two o'clock in the morning and would often show up at appointments in subzero temperatures. His generosity extended beyond his immediate family. Steven Boster's history includes a number of historical landmarks.
PMID: 9636197 by Tuereci O., et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
PMID: 9770531 by Ivanov S.V., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.